Business Information
The group's principal activity is to discover and develop breakthrough, proprietary products for the treatment of serious medical diseases. The group has expertise in both protein-based and small molecule therapeutics. The group combines its capabilities in molecular, cellular and structural biology, high throughput drug screening, medicinal chemistry and gene expression profiling to develop these products. The group applies its integrated approach to erectile dysfunction and other urologic disorders, sepsis, psoriasis and other inflammatory diseases. The group and its collaboration partners have the following product candidates in development: cialis (tadalafil), for the treatment of erectile dysfunction; ic747, for the treatment of psoriasis inflammatory diseases; rtxtm, for the treatment of interstitial cystitis; ic14, for the treatment of sepsis resulting from community acquired pneumonia and ic485, for the treatment of chronic obstructive pulmonary disease.
|
|
Name |
Title
|
Email
|
| Kevin Egan | Dir. - Business Development | Available
|
|
|
Year |
Sales |
Net Income |
| 2005 | 90,929 | (74,842) | | 2004 | 74,608 | (198,248) | | 2003 | 75,104 | (125,507)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
